Lebrikizumab for Idiopathic Pulmonary Fibrosis
Lebrikizumab is an experimental drug aimed at treating inflammatory and fibrotic diseases. Owing to its immunosuppressive potential, it has been tested against diseases like asthma and refractory Hodgkin’s Lymphoma with successful results. Currently, the company is also pursuing studies to test its use in Idiopathic Pulmonary Fibrosis.
Lebrikizumab was first developed by Texas-based biopharmaceutical company Tanox under the name TNX-650. Genentech acquired Tanox in 2007 and initiated successful clinical trials, testing the therapy in refractory Hodgkin’s Lymphoma and asthma.